首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   13177篇
  免费   1344篇
  国内免费   424篇
耳鼻咽喉   56篇
儿科学   76篇
妇产科学   53篇
基础医学   755篇
口腔科学   921篇
临床医学   1054篇
内科学   654篇
皮肤病学   42篇
神经病学   408篇
特种医学   440篇
外科学   782篇
综合类   1949篇
一般理论   3篇
预防医学   2020篇
眼科学   80篇
药学   3639篇
  17篇
中国医学   1814篇
肿瘤学   182篇
  2024年   4篇
  2023年   261篇
  2022年   304篇
  2021年   488篇
  2020年   531篇
  2019年   513篇
  2018年   493篇
  2017年   517篇
  2016年   517篇
  2015年   546篇
  2014年   908篇
  2013年   1435篇
  2012年   944篇
  2011年   990篇
  2010年   713篇
  2009年   713篇
  2008年   788篇
  2007年   707篇
  2006年   603篇
  2005年   528篇
  2004年   364篇
  2003年   303篇
  2002年   279篇
  2001年   250篇
  2000年   203篇
  1999年   141篇
  1998年   105篇
  1997年   105篇
  1996年   78篇
  1995年   62篇
  1994年   72篇
  1993年   75篇
  1992年   65篇
  1991年   42篇
  1990年   37篇
  1989年   36篇
  1988年   40篇
  1987年   32篇
  1986年   25篇
  1985年   24篇
  1984年   19篇
  1983年   12篇
  1982年   12篇
  1981年   13篇
  1980年   15篇
  1979年   5篇
  1978年   5篇
  1977年   7篇
  1976年   5篇
  1974年   3篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
The Extracellular Vesicle Flow Cytometry Working Group ( http://www.evflowcytometry.org ) is formed by members of the International Society for Extracellular Vesicles (ISEV), the International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH). This working group of flow cytometry experts develops guidelines for best practices regarding flow cytometry detection of extracellular vesicles. To improve rigor and standardization, this working group published a framework outlining the minimal information to report about a flow cytometry experiment on extracellular vesicles (MIFlowCyt-EV) in the Journal of Extracellular Vesicles, the ISEV journal, in 2020. In parallel, an article explaining MIFlowCyt-EV was published in Cytometry Part A, one of the ISAC journals, and now will be introduced to the ISTH as an SSC Communication in the Journal of Thrombosis and Haemostasis. The goal of this SSC Communication is to explain why flow cytometry is becoming the instrument of choice to characterize single extracellular vesicles, the obstacles that have been identified and (mostly) overcome by developing procedures to calibrate flow cytometers, and the relevance of reporting minimal information to improve reliability and reproducibility of experiments in which flow cytometers are used for characterization of extracellular vesicles.  相似文献   
2.
ObjectivesPreclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to standard treatment and the secondary aims its effect on cognition and slowing disease progression.DesignRandomized double-blind placebo-controlled delayed-start study.Setting and ParticipantPatients with mild to moderate probable AD by NINCDS-ADRDA criteria, stable on acetylcholinesterase inhibitors or memantine (n = 125), were randomized to receive MLC901 (early starters) or placebo (delayed starters) for 6 months, followed by a further 6 months when all patients received MLC901, in a delayed-start design (clinical trial registration: ClinicalTrials.gov, NCT03038035).MethodsThe primary outcome measure was occurrence of serious adverse events (SAEs) at 6 months. Secondary outcomes included the Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog) and other assessment scales.ResultsThere was no significant difference in the risk of SAEs between early and delayed starters at month (M) 6 (22.6% vs 27.0%, risk difference ?4.4%, 90% CI –16.9% to 8.3%). Similarly, there was no significant difference in the risk of adverse events and the occurrence of stroke or vascular events between early and delayed starters throughout the 12-month study period. Early starters did not differ significantly on ADAS-Cog from delayed starters at M6 [mean difference (MD) ?1.0, 95% CI –3.3 to 1.3] and M12 (MD –2.35, 95% CI –5.45 to 0.74) on intention-to-treat analysis. Other cognitive assessment scales did not show significant differences.Conclusions and ImplicationsThis study of 125 persons with dementia found no evidence of a significant increase in adverse events between MLC901 and placebo, thus providing support for further studies on both efficacy and safety. Analyses suggest the potential of MLC901 in slowing down AD progression, but this requires further confirmation in larger and longer studies using biomarkers for AD.  相似文献   
3.
【目的】 总结科技期刊封面设计流程管理模式并探讨其中的相关问题,为同行提供经验借鉴。【方法】 从版面、设计风格等方面对科技期刊封面图片的特征进行归纳。以中国激光杂志社期刊封面为例,总结封面设计流程管理模式,探讨封面设计过程中的相关问题。【结果】 期刊应对封面的主题策划、生产流程、版权保护等方面进行有效的流程管理。此外,就封面设置及风格、元素文化、版权意识、与设计公司合作等问题进行思考总结。【结论】 科技期刊可通过合理的封面设计流程,将科技与艺术融合,更准确地传播前沿科技成果,并弘扬中国传统文化。  相似文献   
4.
目的优选超声靶向微泡破坏(UTMD)技术介导载基因靶向纳米泡(T-NB)爆破的条件。方法采用薄膜水化法制备纳米泡,以生物素-亲和素-生物素连接方法制备pAd-AAV-9/miRNA-1 T-NB,观察其基本理化性质。基于机械指数(0.6、0.9、1.2、1.5)、T-NB溶液浓度(10^(5)/ml、10^(6)/ml、10^(7)/ml、10^(8)/ml)及辐照时间(30、45、60、120 s)设计三因素四水平正交实验,评价不同超声辐照参数对T-NB溶液信号强度的影响。结果pAd-AAV-9/miRNA-1 T-NB溶液为乳白色混悬液,浓度(0.74±0.10)×10^(8)/ml;T-NB为大小相近的球形,平均粒径(443.97±12.84)nm,平均电位(-7.33±0.09)mV。在不同辐照条件下,T-NB溶液的信号强度不同。机械指数、T-NB浓度及辐照时间均可显著影响信号强度(P均<0.05)。影响T-NB爆破的因素依次为机械指数、T-NB溶液浓度及辐照时间,机械指数0.6、T-NB浓度10^(6)/ml、辐照时间120 s为其最优组合。结论机械指数0.6、T-NB溶液浓度10^(6)/ml、辐照时间120 s为UTMD技术载基因T-NB的最优爆破条件。  相似文献   
5.
 目的 调查医院感染预防与控制课程设计中医学生的教育需求及教师的课程设计建议。方法 采用问卷调查全国5个地区10所医学院校师生的医院感染预防与控制教育需求和课程设计意见,参考塔巴目标模式课程设计步骤,论证课程设计方案。结果 584名学生中,仅11.8%(69名)的学生认为当前医院感染预防与控制教育能完全满足其需求,需求得分居前四位的为手卫生、消毒灭菌隔离、医院感染概论和职业防护。352名教师中,72.7%(256名)建议设必修课;86.4%(304名)选择总学时8~24学时,12.5%(44名)选择24学时以上,被调查教师建议10个章节学时平均总和为19.5;需重点掌握13项、熟悉9项知识和技能;86.4%(304名)教师建议理论与见习学时比为1 ∶0.5及以上;53.4%(188名)教师建议采取理论大课+小组见习(含技能操作)+线上学习的形式;63.7%(224名)教师建议师资团队由医院感染管理科+感染病科+护理部教师共同组成。结论 当前医学生的医院感染预防与控制教育远未完全满足需求,单独开课很有必要,建议设置16~24学时必修课,理论联系实践,多学科师资实施多元化教学,按照必修课考核。  相似文献   
6.
《Drug discovery today》2022,27(1):82-101
WNT/β-catenin signaling orchestrates various physiological processes, including embryonic development, growth, tissue homeostasis, and regeneration. Abnormal WNT/β-catenin signaling is associated with various cancers and its inhibition has shown effective antitumor responses. In this review, we discuss the pathway, potential targets for the development of WNT/β-catenin inhibitors, available inhibitors, and their specific molecular interactions with the target proteins. We also discuss inhibitors that are in clinical trials and describe potential new avenues for therapeutically targeting the WNT/β-catenin pathway. Furthermore, we introduce emerging strategies, including artificial intelligence (AI)-assisted tools and technology-based actionable approaches, to translate WNT/β-catenin inhibitors to the clinic for cancer therapy.  相似文献   
7.
正颌手术后髁突移位可导致患者复发以及出现颞下颌关节症状。为减少术后髁突移位,众多髁突定位技术运用于临床中。旨探讨髁突定位技术预防术后出现关节症状及复发的有效性,本文回顾近20年内国内外正颌术中髁突定位技术的相关文献,经文献归纳发现,定位技术以稳定术前髁突位置为最终目的,可分为非计算机辅助和计算机辅助定位技术。目前计算机辅助设计与制造髁突定位装置(computer?aided de?sign/computer?aided manufacturing condylar positioning devices,CAD/CAM CPDs)定位效果最佳,由牙支持式与骨支持式导板组成。其余各技术定位效果由高到低排序:CAD/CAM钛板定位>手法定位>计算机辅助导航系统>影像定位系统。各定位技术的精准度可达到与髁突术前位置相差1~2 mm与1°~2°,有效预防术后复发以及关节症状,为不同级别的外科医生和不同难度的病例提供临床参考。该领域仍缺乏大样本和长时间随访的随机对照试验。未来需进一步研究,以优化现今髁突定位技术,提升其临床实际效用及开拓新型定位技术。  相似文献   
8.
The aim of this study was to investigate the accuracy of a previously described technique for guided biopsy of osseous pathologies of the jawbone in a clinical setting. The data sets of patients who had undergone guided biopsy procedures were retrospectively examined for accuracy. Digital planning of the biopsies and manufacturing of the tooth-supported drilling template were performed with superimposed cone beam computed tomography and intraoral scans using implant planning software. After a trephine biopsy was taken using the template, the postoperative low-dose cone beam computed tomography was analyzed for accuracy using the planning software with the corresponding (digitally-planned) biopsy cylinder. The mean angular deviation was 4.35 ± 2.5°. The mean depth deviation was ?1.40 ± 1.41 mm. Guided biopsy seems to be an alternative to a conventional approach for minimally invasive and highly accurate jawbone biopsy.  相似文献   
9.
目的 制备性状良好的土元凝胶贴膏。方法 采用单因素试验结合Box-Behnken设计响应面法,以初黏力、持黏力和剥离强度为评价指标,对土元凝胶贴膏基质配比进行优选,同时使用正交设计法筛选最佳载药量。结果 最佳基质配比为聚丙烯酸钠(NP-700)10.00 g、甘羟铝0.40 g、酒石酸0.32 g、甘油36.00 g、高岭土8.00 g、水24.00 g,载药10%土元冻干粉。结论 优选得到的凝胶贴膏黏性适中、剥离强度小,可用于后续土元凝胶贴膏的开发与应用。  相似文献   
10.
When a new treatment regimen is expected to have comparable or slightly worse efficacy to that of the control regimen but has benefits in other domains such as safety and tolerability, a noninferiority (NI) trial may be appropriate but is fraught with difficulty in justifying an acceptable NI margin that is based on both clinical and statistical input. To overcome this, we propose to utilize composite risk‐benefit outcomes that combine elements from domains of importance (eg, efficacy, safety, and tolerability). The composite outcome itself may be analyzed using a superiority framework, or it can be used as a tool at the design stage of a NI trial for selecting an NI margin for efficacy that balances changes in risks and benefits. In the latter case, the choice of NI margin may be based on a novel quantity called the maximum allowable decrease in efficacy (MADE), defined as the marginal difference in efficacy between arms that would yield a null treatment effect for the composite outcome given an assumed distribution for the composite outcome. We observe that MADE: (1) is larger when the safety improvement for the experimental arm is larger, (2) depends on the association between the efficacy and safety outcomes, and (3) depends on the control arm efficacy rate. We use a numerical example for power comparisons between a superiority test for the composite outcome vs a noninferiority test for efficacy using the MADE as the NI margin, and apply the methods to a TB treatment trial.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号